ARCHIVES

Sorafenib Targets AML Driven By Mutant FLT3 Gene

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

Some Tumors Show Partial Response To Drug Combo

January 27, 2006

In Brief: Beahrs Headed Team For President’s Surgery; Chiles Chairs HHS Appropriations Subcommittee

January 9, 1987

In Brief: GAO Studying Cancer Program So Congress Will Have Own Data; NCI Job Freeze Still Hurts Program

February 21, 1975

DCBDC Bard Approves Expansion Of SPORE Program To GY Cancers; Okays Two other RFAs

December 4, 1992

Authorizes $2.7 Billion For NCI, 7% Prevention

May 28, 1993

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

November 1, 2012